Research Team -
Paediatric Haematology and Oncology
Dr. CHUNG Po Yee, Bowie
Dr. WANG Han
Dr. XU Yaqun
Dr. ZHANG Chi, Sally
Mr. CHEUNG Tak Kit, John
Ms. FOK Siu Ping, Queenie
Ms. LEE Po Yi, Polly
Ms. LEUNG Wai Man, Gloria
Ms. WU Yixuan, Victoria
Ms. XU Qianhan
Ms. CHUNG Kin Yi, Kella (MPhil)
Ms. LIN Guanglan, Christie (PhD)
Ms. NG Wing Hei Ng, Kobby (MPhil)
Mr. SUN Qiwei (PhD)
Ms. YANG Yunni (MPhil)
An overview of research focus
Our team, comprises of renowned paediatric oncologists, haematologists and pathologists, has a long-standing research interest in clinical and translational haematology, and is dedicated to develop new treatment modalities for children suffering from leukemia. The research site is located at the Hong Kong Children’s Hospital where all childhood leukemia cases are now being centralized for management.
A list of research topics
Clinical trials for childhood leukemia
Minimal residual disease monitoring
Leukemia immunology and chimeric antigen receptor T cells
Therapeutic antibodies and small-molecule inhibitors
Functional genomics and precision medicine
Single-cell transcriptomics and high-dimensional analyses
Molecular mechanisms of hematopoietic stem cell transplantation
Wang H, Chan KY, Cheng CK, Ng MH, Lee PY, Cheng FW, Lam GK, Chow TW, Ha SY, Chiang AK, Leung WH, Leung AY, Wang CC, Zhang T, Zhang XB, So CC, Yuen YP, Sun Q, Zhang C, Xu Y, Cheung JT, Ng WH, Tang PM, Kang W, To KF, Lee WY, Wong RS, Poon EN, Zhao Q, Huang J, Chen C, Yuen PM, Li CK, Leung AW, Leung KT. Pharmacogenomic profiling of pediatric acute myeloid leukemia to identify therapeutic vulnerabilities and inform functional precision medicine. Blood Cancer Discov. 2022; 3(6):516-535.
Yang W, Cai J, Shen S, Gao J, Yu J, Hu S, Jiang H, Fang Y, Liang C, Ju X, Wu X, Zhai X, Tian X, Wang N, Liu A, Jiang H, Jin R, Sun L, Yang M, Leung AWK, Pan K, Zhang Y, Chen J, Zhu Y, Zhang H, Li C, Yang JJ, Cheng C, Li CK, Tang J, Zhu X, Pui CH. Pulse therapy with vincristine and dexamethasone for childhood acute lymphoblastic leukaemia (CCCG-ALL-2015): an open-label, multicentre, randomised, phase 3, non-inferiority trial. Lancet Oncol.2021;22(9):1322-1332.
Fan POL, Leung KT, Chan KYY, Leung AWK, Lam GKS, Chow TTW, Cheng FWT, Yuen LYP, Moriyama T, Yang JJ, Li CK. ABCC4, ITPA, NUDT15, TPMT and their interaction as genetic predictors of 6-mercaptopurine intolerance in chinese patients with acute lymphoblastic leukemia. Pediatr Hematol Oncol. 2021; 1-13.
Chan KYY, Zhang C, Wong YTS, Zhang XB, Wang CC, Ng WH, Fok SP, Tang PMK, Kang W, Feng B, Poon ENY, Lee KY, Lee CK, Chen C, Leung TY, Ng MHL, To KF, Wang H, Lam HS, Ng PC, Yuen PMP, Li K, Leung AWK, Li CK, Leung KT. R4 RGS proteins suppress engraftment of human hematopoietic stem/progenitor cells by modulating SDF-1/CXCR4 signaling. Blood Adv. 2021; 5(21):4380-4392.
Feng J, Lee V, Leung AWK, Lam GKS, Chow TTW, Cheng FWT, Yan CLS, Lee CK, Yuen PMP, Li CK. Double-unit unrelated cord blood transplantation for thalassemia major: comparison with HLA-identical sibling bone marrow transplantation. Pediatr Transplant. 2021; 25(3):e13901.
Leung KT, Zhang C, Chan KYY, Li K, Cheung JTK, Ng MHL, Zhang XB, Sit T, Lee WYW, Kang W, To KF, Yu JWS, Man TKF, Wang H, Tsang KS, Cheng FWT, Lam GKS, Chow TW, Leung AWK, Leung TF, Yuen PMP, Ng PC, Li CK. CD9 blockade suppresses disease progression of high-risk pediatric B-cell precursor acute lymphoblastic leukemia and enhances chemosensitivity. Leukemia. 2020; 34(3):709-720.
Zhu Y, Yang R, Cai J, Yu J, Tang Y, Chen Y, Wang N, He H, Wu X, Cheng FWT, Sun L, He Y, Ju X, Tian X, Hu Q, Jin R, Pan K, Fang Y, Zhai X, Jiang H, Li CK. Septicemia after chemotherapy for childhood acute lymphoblastic leukemia in China: A multicenter study CCCG-ALL-2015. Cancer Med. 2020; 9(6):2113-2121.
Cui L, Li ZG, Chai YH, Yu J, Gao J, Zhu XF, Jin RM, Shi XD, Zhang LP, Gao YJ, Zhang RD, Zheng HY, Hu SY, Cui YH, Zhu YP, Zou Y, Ng MHL, Xiao Y, Li JH, Zhang YH, He HL, Xian Y, Wang TY, Li CK, Wu MY; Chinese Children Leukemia Group (CCLG). Outcome of children with newly diagnosed acute lymphoblastic leukemia treated with CCLG-ALL 2008: The first nation-wide prospective multicenter study in China. Am J Hematol. 2018; 93(7):913-920.
Tsang KS, Leung AW, Lee V, Cheng FW, Shing MM, Pong HN, Leung TF, Yuen PM, Li CK. Indiscernible benefit of double-unit umbilical cord blood transplantation in children: a single-center experience from Hong Kong. Cell Transplant. 2016; 25(7):1277-1286.
Leung KT, Chan KY, Ng PC, Lau TK, Chiu WM, Tsang KS, Li CK, Kong CK, Li K. The tetraspanin CD9 regulates migration, adhesion, and homing of human cord blood CD34+ hematopoietic stem and progenitor cells. Blood.2011; 117(6):1840-1850.
1. Study title: First-in-class CD9 inhibitor for acute lymphoblastic leukemia
Funding source: Innovation and Technology Commission – Innovation and Technology Fund (Seed Project)
Study period: 01 Feb 2023 to 31 Jul 2024
Reference number: ITS-182-21
2. Study title: Histone hypoacetylation-driven CD9 repression in pediatric acute myeloid leukemia: a new mechanism intertwining differentiation arrest and immune escape
Funding source: Research Grants Council – Early Career Scheme
Study period: 01 Jan 2023 to 30 Jun 2025
Reference number: 24121922
3. Study title: Local Manufacturing and Development of Clinical Scale Chimeric Antigen Receptor Modified T Cell (CAR T) for Treatment of Haematological Malignancies
Funding source: Innovation and Technology Commission – Innovation and Technology Fund (Platform Project)
Study period: 01 Jul 2021 to 30 Jun 2023
Reference number: ITS/153/20FP
4. Study title: Driving Therapeutic Progress of Childhood Leukemia through Advanced Translational Research with Immediate and Long-term Impact
Funding source: Food and Health Bureau – Health and Medical Research Fund (Commissioned Project)
Study period: 01 Apr 2021 to 31 Mar 2024
Reference number: PR-CUHK-1
5. Study title: Research and development of novel targeted therapeutic agents for high-risk pediatric B-precursor acute lymphoblastic leukemia
Funding source: Innovation and Technology Commission – Innovation and Technology Fund (Partnership Project)
Study period: 01 Nov 2019 to 30 Apr 2022
Reference number: UIM/401
6. Study title: A novel preclinical treatment strategy for enhancing chemosensitivity of pediatric B-precursor acute lymphoblastic leukemia by disruption of leukemia-stroma interaction using CD9-neutralizing antibody
Funding source: Research Grants Council – General Research Fund
Study period: 01 Jan 2016 to 31 Dec 2018
Reference number: 14108615
St. Jude Children’s Research Hospital (USA), Loma Linda University (USA), University of Birmingham (UK), Medical University of Vienna (Austria)
Sun Yat-Sen University 7th Hospital (Shenzhen): Training and research collaboration (2020-2024), University of Macau
News of the team
Recent research findings
Tailoring functional precision medicine for children with difficult-to-treat leukemia (Blood Cancer Discovery, 2022)
Discovery of RGS proteins in human hematopoietic stem cells (Blood Adv, 2021)
CD9 blockade effectively ameliorates pediatric acute lymphoblastic leukemia (Leukemia, 2020)
Awards of team members
Schweisguth Prize, International Society of Paediatric Oncology (SIOP), 2022 to Wang H.
Young Investigator Award, International Society of Paediatric Oncology (SIOP), 2020 to Wang H, 2021 to Xu Y.
Abstract Achievement Award, American Society of Hematology (ASH), 2021 to Xu Y and Wang H.
Travel Scholarship, British Society of Haematology (BSH), 2021 to Xu Y.
Travel Award, European Haematology Association (EHA), 2019 to Zhang C, 2022 to Xu Y and Ng WH.
Award for Oral Presentation, Hong Kong Paediatric Society, 2019 to Wang H, 2021 to Xu Y, 2022 to Ng WH.
Best Oral Presentation Award, Asian Society of Pediatric Research, 2017 to Zhang C.
Children’s Cancer Foundation: 2013, 2017, 2021
Children’s Thalassemia Foundation: 2013, 2018
Billion Charity Fund 2019
Winnie Yu Tong Fund 2020
Opportunities to research students
3-4 year training for PhD, 2 year training for MPhil
Advanced technologies in hematology/oncology
Cutting edge clinical and translational research in childhood leukemia
International exposure through exchange and conference attendance
Robust system of team research activities